Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
What happened
FDA reviewed records the company submitted after a March 25, 2024 records request under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act; this was a records review, not an inspection. FDA found the quality unit did not adequately qualify API suppliers, including three suppliers on FDA import alert (a detention list), and that laboratory controls did not ensure microbiological quality. The company had not tested numerous batches for Burkholderia cepacia complex (BCC) and had not conducted antimicrobial effectiveness testing (AET); it recalled OneLAX Docusate Sodium Liquid Stool Softener Laxative on October 15, 2024.
What FDA found
The quality control unit lacked adequate authority and did not qualify API suppliers; three API suppliers were on FDA import alert when products were made and shipped to the U.S.
21 CFR 211.22(a)Laboratory controls were inadequate to ensure identity, strength, quality, and purity, including microbiological quality.
21 CFR 211.160(b)Numerous drug product batches were not tested for Burkholderia cepacia complex before release, and OneLAX specifications did not include it.
21 CFR 211.160(b)The company lacked specifications to ensure a component used in its drugs was suitable and did not test it for Burkholderia cepacia complex.
21 CFR 211.160(b)The company did not conduct antimicrobial effectiveness testing on multi-dose drug products, including products labeled for infants and children.
21 CFR 211.160(b)
What FDA wants
FDA tells the company to correct violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. It also asks for comprehensive remediation plans, an independent supplier and material review, microbial risk assessments and testing, and recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drugs from Akron as a contract manufacturer
- distributors and retailers selling OneLAX or other Akron products
- companies that rely on API suppliers with import alerts
This is a summary. Read the original letter on fda.gov.